News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apogee Technology, Inc. (ATA) Resumes Trading on the OTC Bulletin Board



1/27/2011 8:39:06 AM

NORWOOD, MA--(Marketwire - January 26, 2011) - Apogee Technology (OTCBB: ATCS), a life sciences company focused on the development of vaccine and drug delivery systems, today announced that its shares have resumed trading on the Over The Counter Bulletin Board under the symbol ATCS.OB.

About Apogee Technology, Inc.

Apogee Technology, Inc. was organized as a Delaware corporation in 1987, and is currently focused on the development of advanced vaccine delivery systems, including formulations and devices for immunoadjuvants and ID immunization. It has a unique expertise in the polyphosphazene immunoadjuvant technology. Dr. Alexander Andrianov, its Vice President of Research and Development, is the inventor of the technology and is instrumental in advancing it to clinical trials. Apogee's highly skilled scientific team has a combined 50+ years experience in biotechnology, polymer science, and vaccine delivery and have authored numerous peer-reviewed publications and patents. For more information, please visit our web site at: http://www.apogeebio.com.

PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders.

Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve those related to the use of proceeds from the private placement, the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the Company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its report on Form 10-KSB, as amended, for the year ended December 31, 2007, as updated in its quarterly reports on Form 10-Q. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.


Apogee Investor Contact:
Paul J. Murphy
Chief Financial Officer and Vice President of Finance
Telephone: (781) 551-9450


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES